TY - JOUR AU - Allemani, C. AU - Matsuda, T. AU - Carlo, V. D. PY - 2018 DA - 2018// TI - Global surveillance of trends in cancer survival: analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000–2014 from 322 population-based registries in 71 countries (CONCORD-3) JO - Lancet. VL - 391 UR - https://doi.org/10.1016/S0140-6736(17)33326-3 DO - 10.1016/S0140-6736(17)33326-3 ID - Allemani2018 ER - TY - JOUR AU - Bianco, R. AU - Caputo, R. AU - Caputo, R. PY - 2004 DA - 2004// TI - Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0497 DO - 10.1158/1078-0432.CCR-03-0497 ID - Bianco2004 ER - TY - JOUR AU - Castellanos, E. AU - Feld, E. AU - Horn, L. PY - 2017 DA - 2017// TI - Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.12.014 DO - 10.1016/j.jtho.2016.12.014 ID - Castellanos2017 ER - TY - JOUR AU - Feng, F. Y. AU - Zhang, Y. AU - Kothari, V. PY - 2016 DA - 2016// TI - MDM2 inhibition sensitizes prostate Cancer cells to androgen ablation and radiotherapy in a p53-dependent manner JO - Neoplasia. VL - 18 UR - https://doi.org/10.1016/j.neo.2016.01.006 DO - 10.1016/j.neo.2016.01.006 ID - Feng2016 ER - TY - JOUR AU - Gandhi, J. AU - Zhang, J. AU - Xie, Y. PY - 2009 DA - 2009// TI - Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines JO - PLoS One VL - 4 UR - https://doi.org/10.1371/journal.pone.0004576 DO - 10.1371/journal.pone.0004576 ID - Gandhi2009 ER - TY - JOUR AU - Golding, B. AU - Luu, A. AU - Jones, R. PY - 2018 DA - 2018// TI - The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0810-4 DO - 10.1186/s12943-018-0810-4 ID - Golding2018 ER - TY - JOUR AU - Hou, H. L. AU - Ge, C. AU - Sun, H. F. PY - 2018 DA - 2018// TI - Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway JO - Cancer Sci VL - 9 UR - https://doi.org/10.1111/cas.13518 DO - 10.1111/cas.13518 ID - Hou2018 ER - TY - JOUR AU - Hou, H. L. AU - Sun, D. T. AU - Liu, K. W. PY - 2019 DA - 2019// TI - The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S190098 DO - 10.2147/CMAR.S190098 ID - Hou2019 ER - TY - JOUR AU - Hou, H. L. AU - Sun, D. T. AU - Zhang, X. C. PY - 2019 DA - 2019// TI - The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors JO - Cancer Cell Int VL - 19 UR - https://doi.org/10.1186/s12935-019-0937-4 DO - 10.1186/s12935-019-0937-4 ID - Hou2019 ER - TY - JOUR AU - Hou, H. L. AU - Zhu, H. AU - Zhao, H. PY - 2018 DA - 2018// TI - Comprehensive molecular characterization of young chinese patients with lung adenocarcinoma identified a distinctive genetic profile JO - Oncologist. VL - 23 UR - https://doi.org/10.1634/theoncologist.2017-0629 DO - 10.1634/theoncologist.2017-0629 ID - Hou2018 ER - TY - JOUR AU - Inukai, M. AU - Toyooka, S. AU - Ito, S. PY - 2006 DA - 2006// TI - Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-1951 DO - 10.1158/0008-5472.CAN-06-1951 ID - Inukai2006 ER - TY - JOUR AU - Kato, S. AU - Goodman, A. AU - Walavalkar, V. PY - 2017 DA - 2017// TI - Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3133 DO - 10.1158/1078-0432.CCR-16-3133 ID - Kato2017 ER - TY - JOUR AU - Kim, Y. AU - Lee, B. AU - Shim, J. H. PY - 2019 DA - 2019// TI - Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2018.10.150 DO - 10.1016/j.jtho.2018.10.150 ID - Kim2019 ER - TY - JOUR AU - Koom, W. S. AU - Park, S. Y. AU - Kim, W. PY - 2012 DA - 2012// TI - Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma JO - J Radiat Res VL - 53 UR - https://doi.org/10.1269/jrr.11110 DO - 10.1269/jrr.11110 ID - Koom2012 ER - TY - JOUR AU - Lee, Y. AU - Lee, G. K. AU - Lee, Y. S. PY - 2014 DA - 2014// TI - Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations JO - Cancer. VL - 120 UR - https://doi.org/10.1002/cncr.28711 DO - 10.1002/cncr.28711 ID - Lee2014 ER - TY - JOUR AU - Li, T. AU - Ling, Y. H. AU - Goldman, I. D. PY - 2007 DA - 2007// TI - Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2923 DO - 10.1158/1078-0432.CCR-06-2923 ID - Li2007 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Paez, J. G. AU - Janne, P. A. AU - Lee, J. C. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science. VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Recondo, G. AU - Facchinetti, F. AU - Olaussen, K. A. PY - 2018 DA - 2018// TI - Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/s41571-018-0081-4 DO - 10.1038/s41571-018-0081-4 ID - Recondo2018 ER - TY - JOUR AU - Santoni-Rugiu, E. AU - Melchior, L. C. AU - Urbanska, E. M. PY - 2019 DA - 2019// TI - Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11070923 DO - 10.3390/cancers11070923 ID - Santoni-Rugiu2019 ER - TY - JOUR AU - Sharma, S. V. AU - Lee, D. Y. AU - Li, B. PY - 2010 DA - 2010// TI - A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations JO - Cell. VL - 141 UR - https://doi.org/10.1016/j.cell.2010.02.027 DO - 10.1016/j.cell.2010.02.027 ID - Sharma2010 ER - TY - JOUR AU - Takezawa, K. AU - Pirazzoli, V. AU - Arcila, M. E. PY - 2012 DA - 2012// TI - HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0108 DO - 10.1158/2159-8290.CD-12-0108 ID - Takezawa2012 ER - TY - JOUR AU - Tan, C. S. AU - Gilligan, D. AU - Pacey, S. PY - 2015 DA - 2015// TI - Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00246-6 DO - 10.1016/S1470-2045(15)00246-6 ID - Tan2015 ER - TY - JOUR AU - Tang, Z. AU - Li, C. AU - Kang, B. PY - 2017 DA - 2017// TI - GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses JO - Nucleic Acids Res VL - 45 UR - https://doi.org/10.1093/nar/gkx247 DO - 10.1093/nar/gkx247 ID - Tang2017 ER - TY - JOUR AU - Turke, A. B. AU - Zejnullahu, K. AU - Wu, Y. L. PY - 2010 DA - 2010// TI - Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC JO - Cancer Cell VL - 17 UR - https://doi.org/10.1016/j.ccr.2009.11.022 DO - 10.1016/j.ccr.2009.11.022 ID - Turke2010 ER - TY - JOUR AU - Wang, S. AU - Su, X. AU - Bai, H. PY - 2015 DA - 2015// TI - Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0210-9 DO - 10.1186/s13045-015-0210-9 ID - Wang2015 ER - TY - JOUR AU - Xu, J. AU - Shen, L. AU - Zhang, B. C. PY - 2016 DA - 2016// TI - HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib JO - Oncol Lett VL - 12 UR - https://doi.org/10.3892/ol.2016.5373 DO - 10.3892/ol.2016.5373 ID - Xu2016 ER - TY - JOUR AU - Yano, S. AU - Wang, W. AU - Li, Q. PY - 2008 DA - 2008// TI - Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1643 DO - 10.1158/0008-5472.CAN-08-1643 ID - Yano2008 ER - TY - JOUR AU - Yoshida, T. AU - Ishii, G. AU - Goto, K. PY - 2015 DA - 2015// TI - Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-0846 DO - 10.1158/1078-0432.CCR-14-0846 ID - Yoshida2015 ER - TY - JOUR AU - Yu, H. A. AU - Suzawa, K. AU - Jordan, E. PY - 2018 DA - 2018// TI - Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2961 DO - 10.1158/1078-0432.CCR-17-2961 ID - Yu2018 ER - TY - JOUR AU - Zhang, M. AU - Liu, S. AU - Chua, M. S. PY - 2019 DA - 2019// TI - SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway JO - Cell Death Dis VL - 10 UR - https://doi.org/10.1038/s41419-019-1856-y DO - 10.1038/s41419-019-1856-y ID - Zhang2019 ER -